Your browser doesn't support javascript.
loading
Antitumor and Antiangiogenic Effects of Aspirin-PC in Ovarian Cancer.
Huang, Yan; Lichtenberger, Lenard M; Taylor, Morgan; Bottsford-Miller, Justin N; Haemmerle, Monika; Wagner, Michael J; Lyons, Yasmin; Pradeep, Sunila; Hu, Wei; Previs, Rebecca A; Hansen, Jean M; Fang, Dexing; Dorniak, Piotr L; Filant, Justyna; Dial, Elizabeth J; Shen, Fangrong; Hatakeyama, Hiroto; Sood, Anil K.
Afiliação
  • Huang Y; Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas.
  • Lichtenberger LM; Department of Gynecologic Oncology, Fudan University Shanghai Cancer Center, Shanghai, P.R. China.
  • Taylor M; Department of Integrative Biology and Pharmacology, The University of Texas Health Science Center at Houston, McGovern Medical School, Houston, Texas.
  • Bottsford-Miller JN; Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas.
  • Haemmerle M; Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas.
  • Wagner MJ; Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas.
  • Lyons Y; Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas.
  • Pradeep S; Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas.
  • Hu W; Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas.
  • Previs RA; Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas.
  • Hansen JM; Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas.
  • Fang D; Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas.
  • Dorniak PL; Department of Integrative Biology and Pharmacology, The University of Texas Health Science Center at Houston, McGovern Medical School, Houston, Texas.
  • Filant J; Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas.
  • Dial EJ; Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas.
  • Shen F; Department of Integrative Biology and Pharmacology, The University of Texas Health Science Center at Houston, McGovern Medical School, Houston, Texas.
  • Hatakeyama H; Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas.
  • Sood AK; Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas.
Mol Cancer Ther ; 15(12): 2894-2904, 2016 12.
Article em En | MEDLINE | ID: mdl-27638860
Assuntos
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Neoplasias Ovarianas / Fosfatidilcolinas / Aspirina / Inibidores da Angiogênese / Neovascularização Patológica / Antineoplásicos Tipo de estudo: Prognostic_studies Limite: Animals / Female / Humans Idioma: En Revista: Mol Cancer Ther Assunto da revista: ANTINEOPLASICOS Ano de publicação: 2016 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Neoplasias Ovarianas / Fosfatidilcolinas / Aspirina / Inibidores da Angiogênese / Neovascularização Patológica / Antineoplásicos Tipo de estudo: Prognostic_studies Limite: Animals / Female / Humans Idioma: En Revista: Mol Cancer Ther Assunto da revista: ANTINEOPLASICOS Ano de publicação: 2016 Tipo de documento: Article